Mirati - oncology?

Quote




















anonymous said:
Why did they make Bill head of Tech Ops now?! He is a bad apple too and has no knowledge of CMC! Big ego with no scientific knowledge! If your going to make changes then don’t by making him in charge (not smart move; he’s sexist too !! him and the former svp two peas in a pod)
They need to bring in someone brand new, maybe this time bring a woman to run the department and get rid of this all male-brother hood at the top. 2 birds 1 stone !
Management should keep going and clean parts of the house ! Recruit ASAP!!
Click to expand...


I agree and support these statements.
bring female leadership. No more boys club period. Uncomfortable environment in Techops. They treat us like we are pawns in their “cmc playbooks” or whatever it’s called. So many presentations of how to do our job then actually letting us do our job that we know how to do …. We are scientists for a reason! Worst decision is putting bill in charge. C suite need to fix department and bring in new people now before more people leave soon…..
 




It’s temporary.
they will hire external
anonymous said:
I agree and support these statements.
bring female leadership. No more boys club period. Uncomfortable environment in Techops. They treat us like we are pawns in their “cmc playbooks” or whatever it’s called. So many presentations of how to do our job then actually letting us do our job that we know how to do …. We are scientists for a reason! Worst decision is putting bill in charge. C suite need to fix department and bring in new people now before more people leave soon…..
Click to expand...
 








They’re delusional. The company is still overvalued by at least 50-60%.



STAT: Who’s going to pay billions for Mirati?


Mirati Therapeutics went from biotech obscurity to buyout-rumor ubiquity thanks to adagrasib, a promising cancer drug aimed at a biological target once considered undruggable. But it remains unclear whether the company, which is reportedly considering a sale, can fetch the multibillion-dollar offer its valuation implies.

The latest Mirati news comes from Bloomberg, which reported yesterdaythat the company has retained an adviser to consider potential takeovers and that big companies have been looking into it, with no deals imminent. The story sent Mirati’s share price, which has been cut nearly in half over the past year, up about 15%.

The problem for Mirati is timing. The FDA is scheduled to make a final decision on adagrasib next month, and while the drug’s approval is not in doubt, it remains unclear whether its label will be more restrictive than the one for Lumakras, an Amgen medicine aimed at the same so-called undruggable target. Beyond that, key data on adagrasib’s benefits for earlier stages of cancer are still on the horizon, making it unclear whether any potential suitor would be willing to pay in excess of $5 billion for the company in the presence of so many unknowns.
 




Are we bought yet?
Employees are disillusioned and disengaged with all the equity being under water. Mass exodus coming after the approval and launch The only hope is getting bought.
 




anonymousw said:
They’re delusional. The company is still overvalued by at least 50-60%.



STAT: Who’s going to pay billions for Mirati?


Mirati Therapeutics went from biotech obscurity to buyout-rumor ubiquity thanks to adagrasib, a promising cancer drug aimed at a biological target once considered undruggable. But it remains unclear whether the company, which is reportedly considering a sale, can fetch the multibillion-dollar offer its valuation implies.

The latest Mirati news comes from Bloomberg, which reported yesterdaythat the company has retained an adviser to consider potential takeovers and that big companies have been looking into it, with no deals imminent. The story sent Mirati’s share price, which has been cut nearly in half over the past year, up about 15%.

The problem for Mirati is timing. The FDA is scheduled to make a final decision on adagrasib next month, and while the drug’s approval is not in doubt, it remains unclear whether its label will be more restrictive than the one for Lumakras, an Amgen medicine aimed at the same so-called undruggable target. Beyond that, key data on adagrasib’s benefits for earlier stages of cancer are still on the horizon, making it unclear whether any potential suitor would be willing to pay in excess of $5 billion for the company in the presence of so many unknowns.
Click to expand...

It’s smart to try and dump the company before people see how shitty and narrow the label is going to be. Sales upside will be severely limited. This is a niche product at best.
 




anonymous said:
Why did they make Bill head of Tech Ops now?! He is a bad apple too and has no knowledge of CMC! Big ego with no scientific knowledge! If your going to make changes then don’t by making him in charge (not smart move; he’s sexist too !! him and the former svp two peas in a pod)
They need to bring in someone brand new, maybe this time bring a woman to run the department and get rid of this all male-brother hood at the top. 2 birds 1 stone !
Management should keep going and clean parts of the house ! Recruit ASAP!!
Click to expand...

LOL, I can tell this is Cheng or one of the social rejects in CPR&D because he can barely speak English. The truth is, Phil got let go because the CMC functions and leaders are a bunch of complaining dysfunctional misfits that made him look bad to the execs. Cheng went out of his way to stab him in the back and succeeded because Phil wasn’t liked which is ironic because Phil hired him twice. Why they asked Bill to lead I don’t know but he’ll fail too because CMC is rotten from top to bottom and can’t be fixed. If other departments at Mirati are this F’d up we’re doomed.
 








anonymous said:
LOL, I can tell this is Cheng or one of the social rejects in CPR&D because he can barely speak English. The truth is, Phil got let go because the CMC functions and leaders are a bunch of complaining dysfunctional misfits that made him look bad to the execs. Cheng went out of his way to stab him in the back and succeeded because Phil wasn’t liked which is ironic because Phil hired him twice. Why they asked Bill to lead I don’t know but he’ll fail too because CMC is rotten from top to bottom and can’t be fixed. If other departments at Mirati are this F’d up we’re doomed.
Click to expand...
 




anonymous said:
LOL, I can tell this is Cheng or one of the social rejects in CPR&D because he can barely speak English. The truth is, Phil got let go because the CMC functions and leaders are a bunch of complaining dysfunctional misfits that made him look bad to the execs. Cheng went out of his way to stab him in the back and succeeded because Phil wasn’t liked which is ironic because Phil hired him twice. Why they asked Bill to lead I don’t know but he’ll fail too because CMC is rotten from top to bottom and can’t be fixed. If other departments at Mirati are this F’d up we’re doomed.
Click to expand...



LOL. Nice try! You clearly have no clue why Phil was let go. Keep guessing though....
You must be in SC since you have such strong opinions on the CMC team.
And yes, your post was racist and uncalled for.
 












anonymous said:
Are we bought yet?
Employees are disillusioned and disengaged with all the equity being under water. Mass exodus coming after the approval and launch The only hope is getting bought.
Click to expand...

You’ll be lucky if you have the choice to leave because new CFO might demand downsizing before company sale. She and her little henchman sidekick AO and the new band of bean counters are running the show now, not Meek. Everything good that Baum built with the pipeline and culture of innovation is being quickly eroded away. Just trying to survive to get my bonus. A buyout at any price would be great!
 




anonymous said:
It’s smart to try and dump the company before people see how shitty and narrow the label is going to be. Sales upside will be severely limited. This is a niche product at best.
Click to expand...

The dismal prospects for the therapy will have to be concealed to get and keep interest from any potential acquirer. Meek is unethical enough to do that though.
 




They are horrible. Why do they get to hire so many people while everyone else need to cut. I can’t even keep track of all the new people. All are useless.

anonymous said:
You’ll be lucky if you have the choice to leave because new CFO might demand downsizing before company sale. She and her little henchman sidekick AO and the new band of bean counters are running the show now, not Meek. Everything good that Baum built with the pipeline and culture of innovation is being quickly eroded away. Just trying to survive to get my bonus. A buyout at any price would be great!
Click to expand...
 




Top Bottom
Back
Quote